Telix Pharmaceuticals Limited (ASX: TLX) announced its March 2022 quarter activities report-

Telix Pharmaceuticals Limited (ASX: TLX)  has released its quarter-ended March 2022 activities report and appendix 4C cash flow statement. The company has shared the drilling program result of the Dianne project.

• The company had a cash reserve of AU$154.7 Mn on 31 March 2022 (as compared to AU$22 Mn on 31 December 2021)
• During the quarter, the company completed a AU$175 Mn institutional placement of new, fully paid ordinary shares at an issue price of AU$7.70 per share. The company has also highlighted that the funds are being used to execute on the company's late-stage clinical studies, advance multiple programs towards commercialization and indication expansion.
• The commercial launch of the company’s lead prostate cancer imaging product, illuccix in the United States was the main focus during the March 2022 quarter.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au